Kuros Biosciences (KURN.SW)

Executive Summary

Kuros Biosciences is a Swiss orthobiologics company commercializing its MagnetOs bone graft portfolio, powered by proprietary NeedleGrip surface technology that enhances osteoinduction and mimics natural bone healing. The company has achieved significant clinical and commercial traction, with MagnetOs products cleared for use in spine, extremities, trauma, and oncology applications. Recent clinical data, including a prospective randomized controlled trial in spinal fusion, demonstrated superior fusion rates compared to autograft, underpinning growing surgeon adoption. Kuros is expanding its US presence and advancing its pipeline, with a strong balance sheet supporting continued R&D and commercialization. The company is well-positioned to capture market share in the large orthobiologics market, driven by favorable clinical evidence and a differentiated technology platform.

Upcoming Catalysts (preview)

• Q3 2026FDA 510(k) clearance for MagnetOs Putty in larger defect sizes80% success
• Q2 2027Enrollment completion of MagnetOs Vital spinal fusion pivotal study90% success
• Q4 2026Presentation of 2-year follow-up data from MagnetOs study at NASS 2026100% success